Introduction
After its introduction in 1958 metyrapone (2-methyl-1,2, -bis-(3-pyridyl)-1-propanone) was studied intensively and was shown to lower production of cortisol and other 11 l-hydroxylated corticosteroids by a relatively selective inhibition of 11/3-hydroxylase.' 2 This ability to lower the level of circulating corticosteroids led to its being adopted in two main diagnostic clinical roles: as a test of ACTH reserve' 3-7 and in the differential diagnosis of Cushing's syndrome.3 7 Reports of its use in treatment have been few and virtually confined to the treatment of adrenal tumours3 8 and the ectopic ACTH syndrome.9 10 It has been claimed that the compensatory rise in plasma ACTH that occurs with the use of adrenocortical enzyme blocking agents in patients with pituitary-dependent Cushing's disease would effectively overcome the blockade.1" 12 Our object was to show that long-term control of patients with pituitary-dependent disease is possible. We elected to treat all patients with oral metyrapone and to give them also a course of external pituitary irradiation (unless contraindicated). Transfrontal hypophysectomy patients were not irradiated: one (case 1) had an infarcted pituitary tumour; one (case 12) had very mild longstanding disease and died of a myocardial infarction soon after treatment with metyrapone was started; and the third (case 13) had an elective transfrontal hypophysectomy after two months' preoperative preparation with metyrapone. After diagnosis, treatment with oral metyrapone was started. An impression of each patient's sensitivity to the drug was gained by following the plasma fluorogenic corticosteroid concentrations every hour for four hours and then at 24 hours during a diagnostic metyrapone test, and the starting dose was selected accordingly. The dose used varied from 0 25 g twice daily to 1 0 g four times daily. The aim was to reduce the mean plasma fluorogenic corticosteroid concentration to 300-400 nmol/l (11 to 14 5 j,g/100 ml). The mean was derived from four to seven separate samples taken over 24 hours. Covering corticosteroid treatment was not given.
During the study patients were readmitted to hospital every three to six months for reassessment of their pituitary and adrenal function. At each admission the "day curve" of plasma cortisol and ACTH (as outlined above) was measured. Whenever possible a 50-g oral glucose tolerance test; a 200 pg intravenous thyrotrophin-releasing hormone (TRH) test for thyrotrophin; a 100-leg intravenous gonadotrophinreleasing hormone (GRH) test for luteinising hormone and folliclestimulating hormone; an insulin tolerance test (unless contraindicted by the presence of ischaemic heart disease); and basal estimations of serum prolactin and testosterone concentrations were also performed. For the insulin-tolerance test soluble insulin 0-15 to 0-3 U/kg body weight was given intravenously, and blood sugar, cortisol, growth hormone (GH), and ACTH were measured. Some of the patients were started on treatment before the prolactin assay was available.
Plasma fluorogenic corticosteroid concentrations were measured by Mattingly's method.14 All other hormones were measured by radioimmunoassay. External The thyrotrophin response to intravenous TRH was suppressed in three patients before treatment (cases 1 and 4 were not studied). In all three the response retumed within 18 months. The gonadotrophin responses to GRH showed no consistent changes. The GH response to hypoglycaemia was impaired (peak <20 mU/l) in all the nine patients who were tested before treatment. After treatment the GH response improved in four of the six who were retested. Basal serum prolactin concentrations rose with time (irrespective of radiotherapy} in all but one of the nine patients in whom more than one value was obtained (fig 1) .
The plasma ACTH concentration rose after the start of treatment from a mean value of 106 ng/l (range 61-233 ng/l) to 227 ng/l (range 140-480 ng/l); the highest mean daily value in any patient in the first showed evidence of worsening sodium and water retention; hypertension did not deteriorate in any patient and ankle swelling tended to improve rather than worsen. But of the seven women who received metyrapone for six months or more five noticed either some deterioration in hirsuties or persistence of acne. In most cases this was only mild, but in one (case 7) it was severe enough to lead to discontinuation of metyrapone; she underwent bilateral adrenalectomy. Her plasma testosterone concentration was very high at 55-5 nmol/l (16-0 ng/ml) (normal female range 0 7-2-7 nmol/l (0-2-0-78 ng/ml). In one patient (case 11) facial hirsuties improved.
Discussion
It has been claimed that adrenal blocking drugs would be ineffective in cases of pituitary-dependent Cushing's disease because the rise in plasma ACTH which accompanies their use would break through the blockade. We have shown, however, that breakthrough does not occur and that long-term clinical control is possible. Indeed, we have only ever seen breakthrough twice, and in each case the patient had the ectopic ACTH syndrome. By controlling the clinical manifestations of disease in our patients metyrapone allowed time for the pituitary irradiation to become fully effective.
Serious side effects were few. No patient had clinical evidence of sodium and water retention. None had the gastrointestinal symptoms that are well recognised in patients undergoing the metyrapone test used for assessing pituitary ACTH reserve. We therefore conclude that gastrointestinal side effects are encountered only when plasma cortisol falls to subnormal concentrations and not when it is carefully controlled. Four patients felt curiously lightheaded for several minutes about 20 minutes after ingesting each dose, but the most troublesome side effect was hirsuties, although in only one patient (case 7) was this serious enough to lead to her treatment being discontinued. In all others who complained the hirsuties took the form of slight coarsening of pre-existing facial hair. Enlargement of the clitoris which was present at diagnosis did not regress or worsen except in one patient (case 7). Some virilisation is to be expected from long-term use of an 11 /-hydroxylase inhibitorthe result of accumulating 11 -deoxycorticosteroids with androgenic properties. There was a correlation between the severity of clinical hirsuties and the height of plasma testosterone values on treatment. The patient with severe virilisation had exceptionally high testosterone concentrations, and the other two patients with concentrations greater than 3-5 nmol/l (1-0 ng/ml) were among those who complained of persistent hirsuties. The testosterone antiserum used in our assay had full cross-reaction with dihydrotestosterone and only partial cross-reaction (02-1 1 %) with androsterone, epitestosterone, androstenediol, DHEA sulphate, and DHEA (unpublished data).
For pituitary-dependent disease we recommend the use of metyrapone to control the clinical manifestations of the disease as an adjunct to definitive treatment with pituitary irradiation by linear accelerator. It would, however, also be suitable as an adjunct to pituitary microdissection, cryosurgery, or implantation and bilateral adrenalectomy. Indeed, we now treat with metyrapone all patients who present with Cushing's syndrome, irrespective of aetiology. Apart from the 13 patients described here we have recently successfully managed four patients with the ectopic ACTH syndrome and three patients with adrenal tumour. By controlling the plasma cortisol concentration with metyrapone the clinical features of the disease rapidly regress. Subsequent surgery, if indicated, is greatly simplified and is less hazardous for the patient. Similarly, if it is difficult to make a final differential diagnosis between the causes of Cushing's syndrome, treatment with metyrapone allows time for investigations to be completed in a patient who may otherwise be critically ill.
